AbbVie: Asthma trials

The registry lists 11 Asthma studies with AbbVie as lead sponsor. 0 are open to participants now and 7 have results posted.

Phase 1 3Phase 2 6Phase 3 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent AsthmaCompletedNCT02443298Phase 2Results posted
• Tolerability and PK of Submicron Budesonide in Children 4 to 11 Years Old With Mild-To-Moderate Stable AsthmaCompletedNCT00995904Phase 2Results posted
• Study of MAP0010 in Asthmatic Children and AdolescentsCompletedNCT00697801Phase 2Results posted
• A Study of 2 Doses of MAP0010 in Asthmatic ChildrenTerminatedNCT00697697Phase 3Results posted
• Safety and Blood Level Study of Unit Dose BudesonideCompletedNCT00627679Phase 1Results posted
• A Study of 2 Doses of MAP0010 and Placebo in Asthmatic ChildrenCompletedNCT00569192Phase 3Results posted
• A Study of 2 Doses of MAP0010 in Adult AsthmaticsCompletedNCT00554970Phase 2Results posted
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Immunogenicity of APG777 in Adults With AsthmaActive, not recruitingNCT06920901Phase 1
• Assessment of the Safety of ABT-308 in Healthy Volunteers and Subjects With AsthmaCompletedNCT00986037Phase 1
• Study of Oglemilast for the Treatment of AsthmaCompletedNCT00322686Phase 2
• Study of Oglemilast for the Prevention of Asthma.CompletedNCT00322283Phase 2